ARID1A and neoplasm: In addition, the HR gene panel without ARID1A remained independently associated with longer overall survival after adjusting for high TMB, type of ICI administered, and tumor type (p = 0.015; hazard ratio, 1.36; 95% CI, 1.06–1.74).